NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Curis, Inc. (CRIS) Stock Analysis

Curis, Inc. (CRIS) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

CRIS

$1.35

−$0.02 (−1.46%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CRIS with… →

CRIS Key Statistics

As of Sep 4, 2026
Trading
Open
$1.37
Previous Close
$1.37
Day's Range
1.30–1.39
52-Week Range
1.30–39.00
Volume
96.90K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
3.00
Valuation
Market Cap
$3.27M
P/E Ratio
0.38
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
0.76
EPS (ttm)Profit attributable to each share over the last twelve months.
3.60
Financials (FY)
Revenue (FY)
$9.44M−13.43%
Net Income (FY)
−$7.58M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
2.43M
1-Year Return
−96.05%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
289.50K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

CRIS Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−93.18%
2025−67.65%
2024−76.00%
2023+15.91%
2022−88.45%
2021−41.88%
2020+381.76%
2019+146.38%
2018−80.29%
2017−77.27%
2016 (partial year)+74.01%

As of September 4, 2026.

CRIS Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$9.44M−$7.58M−80.3%
2024$10.91M−$43.39M−397.8%
2023$10.02M−$47.41M−473.0%
2022$10.16M−$56.67M−557.7%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$9.44M$9.40M−$32.90M−$7.58M−80.3%
2024$10.91M$10.81M−$44.54M−$43.39M−397.8%
2023$10.02M$9.81M−$48.33M−$47.41M−473.0%
2022$10.16M$9.91M−$53.02M−$56.67M−557.7%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

CRIS Valuation vs Biotechnology Median

Median of 656 stocks
MetricCRISBiotechnology medianvs median
P/E0.3812.570.0x the median
P/S ratio0.7615.260.0x the median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Curis, Inc. (CRIS) is capitalised at $3.27M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 20 employees.

The 52-week range on file runs from $1.30 to $39.00. CRIS last closed at $1.35 on September 4, 2026. That is −$0.02 (−1.46%) against the previous close. The latest close sits 3.85% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $9.44M. Against the prior fiscal year total of $10.91M, that is a change of −13.43%. The same year closed with a net loss of $7.58M. The reported profit margin is 0%. Trailing earnings per share are 3.6.

Across the 4 fiscal years on file, revenue moves from $10.16M in 2022 to $9.44M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

CRIS trades at a trailing price-to-earnings ratio of 0.38. That is 0 times the Biotechnology median of 12.57. Measured against sales, the shares trade at 0.76 times revenue. On price-to-sales that is 0 times the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

The reported beta is 3. Annualized volatility over the trailing 10 years is 148.79%. The trailing one-year price return is −96.05%. Measured over 10 years, that is −54.38% a year compounded.

Growth & Income

The record shows no dividend for CRIS.

Across the complete calendar years on file, 2020 returned +381.76% and 2022 returned −88.45%. Of the 9 complete calendar years on file, 3 finished higher. 2026 is still running; the price is −93.18% year to date.

Peer Comparison

Curis, Inc. (CRIS) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Curis, Inc. CRIS $3.27M 0.4
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Curis, Inc. trades at a P/E of 0.4.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Curis, Inc.

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed/refractory primary central nervous system lymphoma. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small-molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreements with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed three programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.

Visit website →